-
11m 47s
-
20m 13s
-
12m 35sPart 10 Panel Discussion
-
10m 53s
-
9m 34s
-
10m 55s
-
15m 19sPart 5 Panel Discussion
-
10m 28s
This on-demand version of the live broadcast provides the latest updates on SGLT2 Inhibition in heart failure.
Dr Harriette Van Spall (McMaster University, Hamilton, CA) and Dr Nandini Gupta (Mackenzie Health, Richmond Hill, CA) chair and co-chair the programme, and are joined by an outstanding international faculty for a series of insightful presentations and discussions.
Note, the live version of this session was CME accredited; this on-demand version is not.
Learning Objectives
- To explore the mechanisms of cardiorenal protection with SGLT2 inhibition
- To examine how the safety-efficacy relationship of SGLT2 inhibitors vary with age, frailty, gender and race
- To break down how SGLT2 inhibitors can be safely and optimally combined with other heart failure pharmacotherapies
- To recognise the prognostic value of NT-proBNP in SGLT2 inhibition
- To assess the merit of ejection fraction in heart failure care
Target Audience
- Primary Care Physicians
- Endocrinologists
- Nephrologists
- Cardiologists
- Nurses
- Pharmacists
- Dietitians
- Diabetes Educators
More from this programme
Part 1
Do the Kidneys Hold Clues to the HF Benefits Of SGLT2 Inhibitors?
Part 2
SGLT2 Inhibition in the Elderly and Frail Patients
Part 3
Gender Differences in Outcomes With SGLT2 Inhibitors
Part 4
Efficacy and Safety of SGLT2 Inhibitors in Black Patients
Part 5
Panel Discussion
| 1 session | |
| Panel Discussion | Watch now |
Part 6
SGLT2 Inhibition in Patients With Improved EF
Part 7
SGLT2 Inhibition With MRAs and ARNis
Part 8
Does NT-proBNP Affect the Efficacy of SGLT2 Inhibitors?
Part 9
Does EF Still Matter in HF Management?
Part 10
Panel Discussion
| 1 session | |
| Panel Discussion | Watch now |
Faculty Biographies
Muthiah Vaduganathan
Co-Director, Center for Cardiometabolic Implementation Science
Dr. Muthiah Vaduganathan is a cardiologist and clinical trialist based in Boston, Massachusetts, United States. He practices at Brigham and Women’s Hospital and holds an academic appointment at Harvard Medical School. Dr. Vaduganathan is internationally recognised for his work at the intersection of cardiovascular, kidney, and metabolic disease, with a particular focus on translating evidence from large-scale clinical trials into routine clinical practice.
Academic History
Dr. Vaduganathan completed his medical training in the United States and pursued advanced postgraduate training in cardiovascular medicine, with a focus on heart failure and preventive cardiology. His academic development has been closely aligned with outcomes research, trial methodology, and translational science, positioning him as a leading investigator in cardio-kidney-metabolic therapeutics.
Career Overview
Dr. Vaduganathan is a Cardiologist and Clinical…